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Summary
We have defined structural features that are apparently important for the binding offour different,
unrelated antigenic epitopes to the same major histocompatibility complex (MHC) class I molecule,
H-2Kd . The four epitopes are recognized in the form of synthetic peptides by cytotoxic T
lymphocytes of the appropriate specificity. By analysis of the relative potency of truncated peptides,
we demonstrated that for each of the four epitopes, optimal antigenic activity was present in
a peptide of 9 or 10 amino acid residues . A comparison of the relative competitor activity of
the different-length peptides in a functional competition assay, as well as in a direct binding
assay based on photoaffinity labeling of the Kd molecule, indicated that the enhanced potency
of the peptides upon reduction in length was most likely due to a higher affinity of the shorter
peptides for the Kd molecule. A remarkably simple motif that appears to be important for the
specific binding of Kd-restricted peptides was identified by the analysis of peptides containing
amino acid substitutions or deletions . The motif consists oftwo elements, a Tyr in the second
position relative to the NH2 terminus and a hydrophobic residue with a large aliphatic side chain
(Leu, Ile, or Val) at theCOON-terminal end of the optimal 9- or 10-mer peptides. We demonstrated
that a simple peptide analogue (AYP6L) that incorporates the motif can effectively and specifically
interact with the Kd molecule . Moreover, all of the additional Kd-restricted epitopes defined thus
far in the literature contain the motif, and itmay thus be useful for the prediction ofnew epitopes
recognized by T cells in the context of this MHC class I molecule .
T lymphocytes recognize antigen in the form of com-
plexes with polymorphic cell surface proteins encoded
by theMHC (reviewed in references 1 and 2) . The two major
subpopulations ofT lymphocytes, CD4+ and CD8+ T cells,
recognize antigen in the context ofMHC class II or class I
molecules, respectively. In many instances, it has been demon-
strated that specific T cells can recognize antigen in the form
of synthetic peptides that correspond to linear sequences of
the native antigen (reviewed in references 3 and 4), provided
the peptides are presented by cells expressing the appropriate
MHC molecules . In recent reports, naturally processed an-
tigens recognized by virus-specific CD8+ CTL were isolated
from infected-cell extracts by chromatographic techniques.
In each case the naturally occurring antigen was identified
as a short peptide composed of eight or nine amino acid
residues (5, 6) .
The molecular details of the binding of antigenic peptides
toMHC molecules are not completely understood. From an
X-ray crystallographic analysis of the HLAA2 class IMHC
molecule, a region for the binding of antigenic peptides has
been proposed (7, 8) . In that model, the peptide binding site
consists of a groove that contains most of the polymorphic
MHC residues. A similar model has been proposed forMHC
class II molecules (9) . More recently, a comparison of the
three-dimensional structure ofHLAA2 with that of a second
humanMHC class I molecule, HLAAw68 (10), revealed that
the antigen binding site contains pockets shaped by poly-
morphic residues. It was suggested that the binding ofamino
acid side chains from antigenic peptides in these pockets could
provide a structural basis for the allele specificity of peptide
binding.
One approach for identifying structural features that confer
on antigenic peptides their ability to interact with particular
MHC molecules has been to compare the relative binding
capacity of different peptides to purified MHC molecules .
Based on the analysis of 'a series ofMHC class II-restricted
antigenic peptides and closely related variants, allele-specific
motifs have been proposed for the MHC class II molecules,
IAd and IEd, in the mouse and HLA-DR in man (11-13) .
Thus far, no allele-specific motifs have been identified forMHC
class I-restricted peptides .
We have developed a functionalcompetition assay (14, 15)
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I molecules. For the antigenic peptide HLAA24 (A24)
170-182, we identified three residues (Tyrl71, Thr178, Leul79)
that appear to allow the peptide to interact with the H-2Kd
class I molecule (16). We demonstrated that a peptide ana-
logue (AYP5TLA) of the A24 peptide that incorporates the
Tyr17t (Y) residue and the Thr17s-Leu179 (TL) pair of residues
separated by a pentaproline spacer was an efficient compet-
itor for at least four different K4-restricted peptides (16, 16a).
Of the three residues in the A24 motif, Tyrl71 appeared
to be the most critical for efficient competitor activity. In
a recent study (16a), we noted that all of the Kd-restricted
CTL epitopes that had been defined in the literature had in
common the presence of at least one Tyr residue. In an anal-
ysis of variant peptides in which Tyr residues were replaced
with Ala, we demonstrated that Tyr was likewise crucial for
the optimal competitor activity of three additional Kd-
restricted peptides, namely nucleoprotein (NP)1 147-158
(R- 156), P198 - .14-24, andPlasmodium berghei circumsporo-
zoite protein (Pb. CS) 249-260. Based on these results, we
proposed that Tyr may function as a strong "anchor" for
binding peptides to the Kd molecule.
Our earlier experiments suggested that the relative posi-
tion of Tyr within the antigenic peptide might also be im-
portant. For a series of homologous Kd-restricted A24 and
CW3 antigenic peptides having in common a COOH ter-
minus at position 182, the most potent peptides both as an-
tigens and competitors were those with the Tyr171 residue
at the second position relative to the NH2 terminus (17). For
peptide P198 - .14-24, the Tyr residue is also situated in the
second position, and truncation of the NH2-terminal residue
rendered the peptide 3-10-fold less active as a competitor
(Maryanski, J.L., and G. Corradin, unpublished observations).
Moreover, the latter peptide (P198 - .15-24) was no longer
recognized by P198-specific CTL (18). For the influenza NP
peptide NP 147-158 (and variant peptide NP 147-158
[R - 156) [19)), the Tyr residue is also located in the second
position, but in this case it is not known whether a trun-
cated NP peptide having Tyr at the NH2 terminus would
retain antigenic or competitor activity. However, according
to a recent report, the naturally presented NP peptide recov-
ered from virus-infected cells appears to correspond to the
sequence TYQRTRALV that contains Tyr in the second po-
sition (6).
For the synthetic peptides that were used to define the
Kd-restricted CTL epitopes of the P. berghei and P yoelii CS
proteins (peptides P.h CS 249-260 and P.y. CS 277-288), the
critical Tyr residues are instead located in the fifth position
(20, 21) . In the present report, we have assessed whether the
position of Tyr within these two homologous malaria CTL
epitopes was likewise important. We found that indeed the
most active CS peptides tested were 9-mer species with Tyr
in the second position. The enhanced activity of the shortened
CS peptides prompted us to synthesize COOH-terminally
truncated versions of the A24, NP, and P198 peptides. For
'Abbreviations used in this paper: CS, circumsporozoite; NP, nucleoprotein.
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each of these peptides, we found a shortened sequence that
was considerably more potent, both as an antigen and as a
competitor, than the peptides that had originallybeen defined.
Furthermore, a comparison of the optimal sequences for the
four antigenic peptides analyzed in this study allows us to
suggest the existence of a structural motif that may govern
the binding of peptides to the Kd molecule and hence may
be useful for the prediction of new Kd-restricted antigenic
epitopes.
Materials and Methods
Cells.
￿
The isolation and characterization ofCTL clones specific
for the CS protein of P. berghei (20), of CTL clones specific for
HLA-CW3 (CTIrCW3/1.1 and CTIrCW3/701.1) or HLA-A24
(CTI,A24/10.1) (22), and of CTL clone P198.6 specific for anti-
genic mutant P198 ofthe mouse mastocytoma P815 (23) is described
elsewhere. CTL clones specific for the CS protein ofP. yoelii (YA8
and YB15) were isolated from sporozoite-immune spleen cells of
BALB/c mice (21) following procedures described elsewhere (20).
CTIrNP-B25 was derived from a BALB/c mouse immunized with
influenza peptide NP 147-158 (Romero et al., manuscript in prep-
aration). The latter CTL clones are Kd restricted. CTL clone P91.6
(23), which recognizes the P91 mutant of P815, is Ld restricted.
Peptide Synthesis and Purification.
￿
The Fmoc strategy for solid
phase peptide synthesis was used as described by Merrifield (24)
and by Atherton et al. (25). HPLC-purified peptides were >90%
pure by analytical HPLC. Lyophilized peptides were dissolved in
0.7% sodium bicarbonate buffer or water and further diluted in
DME containing 5% FCS. Amino acid analysis confirmed the ex-
pected peptide composition.
Cytolytic Assay.
￿
P815 cells (106) were labeled with 150 /ACi so-
dium ("Cr) chromate, as described (26), for 1 h at 37°C and
washed three times. Labeled targets (2 x 103) in 50-Etl volumes
were added to wells of V-bottomed microtiter plates containing
100-IA1 volumes of the appropriate peptide diluted in DME sup-
plemented with 5% FCS and 10 mM Hepes. CTL (6 x 103) were
added in 50-Al volumes. After a 4-h incubation at 37°C, the super-
natants (100 gl) were harvested for counting. The percent lysis was
calculated as: 100x [(experimental - spontaneous release)/(total
- spontaneous release)]. Therelative antigenic activity ofthe pep-
tides was calculated for the peptide concentration required to ob-
tain 50% of the maximal lysis. For competition experiments, the
target cells were incubated for 15 min with the competitor peptide
(100-ul volume) before addition of a suboptimal concentration of
the antigenic peptide (50-Ftl volume). CTL (50-ELI volume) were
added after a further 15-min incubation at room temperature. The
plates were then incubated for 4 h at 37°C. The percent control
lysis was calculated as: 100x [(percent lysis with competitor -
backgroundlysis)/(percent lysis without competitor - background
lysis)]. Background lysis represents the percent lysis of the target
cells in the absence ofpeptides. The relative competitor efficiency
of the peptides was calculated for the peptide concentration required
to obtain 50% control lysis.
Competition Assay by Photoainity Labeling.
￿
The H-2Kd photo-
reactive probe (27) used in this study was ('15I)iodo-4-azido
salicyloyl (IASA)YIPSAEK(Biotin)I, a derivativeofthe peptide P .b.
CS 253-260. The compound YIPSAEK(Biotin)I was synthesized
by reacting FmocYIPSAEKI with N-hydroxysuccinimidyl-biotin
(Biotin-ONSu) in DMSO in the presence of1-hydro)xybenzotriazole.
The reaction mixture was treated with piperidineand the resulting
YIPSAEK(Biotin)I derivative was purified by RP-HPLC. Freshlyradioiodinated IASA-ONSu (28, 29) was reacted with YIPSAEK-
(Biotin)I and the (1251) IASAYIPSAEK(Biotin)I derivative was
purified by RP-HPLC. All procedures involvingphotoreactive re-
agents were performed under dimmed light. For photoaffmity
labeling, cells were washed two times in PBS and resuspended in
DMEsupplemented with Hepes (20mM), gentamycin (40lug/ml),
and FCS (0.5%). P815 cells (2 x 106) were incubated with the
(1'sl) IASAYIPSAEK(Biotin)I photoprobe (10' cpm, sp act, 1,700-
2,300Ci/mmol) at a concentration of 3 x 10-9 M in the absence
or presence ofvarious concentrations ofcompetitor peptides in six-
well plates (Costar, Cambridge, MA)at 37°C. Aftera5-h incuba-
tion at 37°C, themixtures were irradiated for 10 minat 4°C with
UV light (15-W lamp with a maximumemission at 312 nm; Bio-
block Scientific, Illkirch, France). The labeled cells were solubi-
lized by adding NP-40 (0.7%) in the presence of iodoacetamide
(10 mM), PMSF (1 mM), and leupeptin (10 lug/ml) on ice. The
samples were then subjectedto immunoprecipitation with the anti-
Kd mAb SFl-1.1.1 as described (27). The samples were analyzed
by SDS-PAGE on 10% linear polyacrylamide gels underreducing
conditions.
Results
EnhancedPotency ofP . yoelii andP. bergheiAntigenicPeptides
ly Truncation at the NH2 Terminus. To determine the op-
timal length of theP. yoelii CTLepitope CS 277-288, several
NH2-terminally truncated peptides were synthesized and
tested for their ability to interact with the Kd molecule in
an indirect functional competition assay. The 9-mer and
8-merpeptides, SYVPSAEQI and YVPSAEQI, respectively,
were at least 30-fold more potent competitors than theorigi-
nally defined 12-mers (Fig. 1 and Table 1). Moreover, when
tested for recognition by two independent P. yoelii-specific
CTL clones, the 9-mer peptide was -100-fold more active
than the 12-mer, and the 8-mer was at least 10-fold more
active. In contrast, the activity of the intermediate-length
Table 1.
￿
Relative Activity of Truncated P. yoelii CS Peptides as Competitors and as Antigens
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Figure 1.
￿
Comparison ofthecompetitor activity ofNH2-terminal trun-
cated P. yoelii CS peptides. s'Cr-labeled P815 target cells were incubated
with the indicated concentrations (final) of competitor peptides corre-
sponding to CS P.y. residues 277-288 (-O-), 278-288 (--F-), 279-288
(-D-), 280-288 (-A,-), 281-288 (-E-), or a peptidefrom a separate syn-
thesis of CS Ry. 277-288 (--0--). The antigenic peptide CW3 170-182
wasadded at a final concentration of 10-7 M, and cells from CTL clone
CW3/1.1 were added at an E/Tratioof5:1. Lysisin theabsence ofcom-
petitor peptides was66%, andlysis in theabsence oftheantigenicpeptide
was 2%.
peptides was not significantly improved compared to the
original 12-mer (Table 1).
A similar panel of P. berghei NH2-terminally truncated
peptides was also prepared. As had been found fortheP .yoelii
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COMPETITOR PEPTIDE (gM)
"' Competitor activity for the CS P. yoelii panel of truncated peptides was assessed with CTL clone CW3/1.1 and antigenic peptide CW3 170-182
(1.5 x 10-7 M for Exp. A and 10-7 M for Exp. B). Control lysis in the absence of competitor peptides was 43% (Exp. A) and 66% (Exp. B),
and lysisin theabsence of antigenicpeptide was<4% . 50% inhibition ofcontrollysis with reference competitor peptide CS Ry. 277-288 wasobtained
at 1.2 x 10 -6 M for Exp. A and 5.6 x 10-7 M for Exp. B. The competitor activity is expressed as the relative concentration of peptide required
to obtain 50% inhibition of control lysis, compared to the CS Ry. 277-288 peptide.
t Antigenic activity of the panel of CS P. yoelii-truncated peptides was assayed with two independent P. yoelii-specific CTL clones. For reference
peptide CS Ry. 277-288, 50% maximal lysis was obtained with 1.5 x 10 -10 M for clone Y.A8, and with 8 x 10-10 M for clone Y.B15. The
antigenicactivity is expressed as the relative concentration of peptiderequired to obtain 50% maximal lysis compared to the CS Ry. 277-288 peptide.
P. yoelii
CS Peptide Sequence Exp.
Relative
Competitor'
A Exp. B
activity as:
Y.A8
Antigen#
Y.B15
277-288 NEDSYVPSAEQI (1) (1) (1) (1)
278-288 EDSYVPSAEQI 0.4 0.4 0.3 0.4
279-288 DSYVPSAEQI 0.7 1.2 3.6 3.5
280-288 SYVPSAEQI 52 56 68 100
281-288 YVPSAEQI 38 33 10 27Competitor activity of the panel of NH2-terminally truncatedCSP.b . peptides was assessed with CTL clone CW3/1.1 and antigenic peptide CW3
170-182 (10 -7 M) . Control lysis in the absence of competitor was 84% and lysis in the absence of antigenic peptide was 10% . 50% inhibition of
control lysis with reference competitor peptide CS PA 249-260 was obtained at 2 x 10-5 M.
5 Competitor activity of the panel of COOH-terminally truncated CS P.b . peptides was assessed with CTL clone CW3/1.1 and antigenic peptide
CW3 170-182 (1.5 x 10-7 M) . Control lysis in the absence of competitor peptide was 66% and lysis in the absence of antigenic peptide was 12% .
50% inhibition of control lysis with reference competitor peptide CS PA 249-260 was obtained at 1 .1 x 10-5 M.
i Competitor activity for the CS P.b. 252-258 peptide was not defined in this experiment . It was similar to the competitor activity of peptide CS
PA 252-259 in an independent experiment .
t Antigenic activity of the panel of N112-terminally truncated CS PA peptides was assayed with CTL clone CS.B28 . For reference peptide CS PA
249-260, 50% maximal lysis was obtained with 5 x 10 -1° M.
11 Antigenic activity of the panel of COOH-terminally truncated CS PA peptides was likewise assessed with CTL clone CS.B28 . 50% maximal
lysis for reference peptide CS P.b. 249-260 was obtained with 2 x 10-9 M.
sequence, both the 9-mer (SYIPSAEKI) and 8-mer (YIP-
SAEKI) P . berghei peptides displayed a considerably higher
competitor activity than the original 12-mer (Table 2) . In
this case, the increase in potencywas at least 40-fold forboth
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peptides. In terms of recognition, the relative activity o£ the
different lengthP . berghei peptides was similar to the relative
competitor activity. However, for CTL clone CS.C1, the in-
crease in antigenic activity of the 8-mer peptide YIPSAEKI
Figure 2.
￿
Comparison of the com-
petitor activity of 9-mer and 12-mer
peptides in a Kd peptide binding assay
based on photoaffinity labeling . P815
cells were incubated with the pho-
toprobe (1251)IASAYIPSAEK(Biotin)I
in the absence or presence of the indi-
cated molar-fold excess of peptides CS
P.h 249-260 (A), CS P.h 252-260 (B),
CSP .y. 277-288 (C), and CS P .y . 280-
288 (D), for5h at 37°C. AfterUV ir-
radiation, the material immunoprecip-
itated by mAbSFi-1.1 .1 (anti-Kd) was
analyzed by SDS-PAGE as described in
Materials and Methods.
Table 2. Relative Activity
P. berghei
CS Peptide
of Truncated P. berghei CS Peptides as Competitors
Sequence
and as Antigens
Relative activity as :
Competitor Antigen
249-260 ND D S Y I P S A E K I (1)* (1),
250-260 DDSYIPSAEK1 2 1
251-260 DSYIPSAEK1 7 3
252-260 SYIPSAEK1 87 104
253-260 Y I P S A E K 1 40 25
249-260 N D D S Y I P S A E K I (1), (1)u
252-262 SYIPSAEKILE 11 15
252-261 SYIPSAEKIL 24 11
252-260 SYIPSAEK1 55 85
252-259 SYIPSAEK 0.3 <10-5
252-258 S Y I P S A E ND, <10-5was only 20-fold (not shown) . The two intermediate-length
P . berghei peptides, DDSYIPSAEKI and DSYIPSAEKI, had
intermediate activities both as antigens and as competitors
(Table 2) .
No Further Improvement in Potency ofthe Highly Active Pep-
tideP . bergheiCS 252-260 by Extension orDeletion at theCOOH
Terminus. The activity of the highly efficient 9-mer peptide
h lx CS 252-260 (SYIPSAEKI) could not be improved by
adding or deleting one or two residues at theCOOH ter-
minus. In fact, as shown in Table 2, the 11-mer peptide SYIP-
SAEKILE was at least fivefold less active both as an antigen
and as a competitor than the 9-mer, and the activity of the
10-mer, SYIPSAEKIL, was decreased by several-fold. More-
over, deletion of the COOH-terminal residue Ilez 6o resulted
in a 100-fold reduction in competitor activity and the pep-
tide was no longer recognized by theCTL clones tested (Table
2, and data not shown) . A similar reduction in activity was
observed for the shortest of the peptides tested, SYIPSAE
(Table 2) .
The Highly Active 9-mer Malaria Antigenic Peptides Are Also
Potent Competitors for a Kd-speck Photoprobe . We have re-
cently demonstrated that photoreactive derivatives of theP .
berghei CTL epitope bind specifically to the Kd molecule in
living cells (27) . Moreover, binding of the radiolabeled pho-
toprobe, IASAYIPSAEK(Biotin)I, to the Kd molecule could
be inhibited by different peptides known to be presented by
Table 3.
￿
Relative Competitor Activity of Truncated Peptides Corresponding to Three Different Kd-restricted CTL Epitopes
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Kd , but not by peptides presented by other class I MHC
molecules . It was thus possible to compare the competitor
activity of the different length malaria peptides in this direct
peptide binding assay . In this experiment, P815 cells (H-2d)
were incubated with the 12-mer or 9-mer peptides corre-
sponding to theP . berghei (NDDSYIPSAEKI and SYIPSAEKI)
orP . yoelii (NEDSYVPSAEQI and SYVPSAEQI) sequences
and the radiolabeled photoprobe at various molar ratios . As
shown in Fig. 2, both 9-mer peptides inhibited the photo-
affinity labeling of the Kd molecule at -100-fold lower con-
centrations than did the corresponding 12-mers . Theseresults
are thus in agreement with those obtained in functional com-
petition experiments.
Other Kd-restricted Antigenic Peptides with Tyr Residues in the
Second Position Also Become More Potent Antigens and Compe-
titors upon Truncation at the COOH Terminus. The significant
increase in antigenic and competitor activity for the malaria
CTL epitopes upon truncation prompted us to ask whether
a similar improvement would be observed for other K'-
restricted antigenic peptides. For this analysis, we chose the
previously defined epitopes HLAA24170-182, influenzaNP
147-158, and P198- .14-24 . For the reasons outlined in the
introduction, the peptide Tyr residues were kept in the second
position, and the sequences were truncated at the 000H-
terminal ends .
As shown in Table 3, truncated peptides that showed a
Competitor activity for antigenic peptide CS PA 252-260 (10-1° M) was assayed with CTL clone CS.B28 . The percent specific lysis in the ab-
sence of competitor was 79%. Percent lysis in the absence of antigenic peptide was 0% . 50% inhibition of lysis for reference A24 peptide, A24
170-182, as a competitor was obtained at 3.5 x 10-6 M, and that for reference NP peptide, NP 147-158, was obtained at 5 x 10-6 M.
t Competitor activity for antigenic peptide CW3 170-182 (3 x 10- s M) was assayed with CTL clone CW3/701.1 . The percent specific lysis in
the absence of competitor was 79% and percent lysis in the absence of antigenic peptide was 4% . 50% inhibition of lysis for reference A24 peptide,
A24 170-182, as a competitor was obtained at 5 x 10 -7 M, and that for reference NP peptide, NP 147-158, was obtained at 6 x 10-7M.
5 Competitor activity for antigenic peptides CS P.b. 252-260 (10 -1° M) and CW3 170-182 (3 x 10-s M) was assayed with CTL clones CS.B28
and CW3/701.1, respectively . The percent specific lysis in the absence of competitor was 66% for CTL CS.B28 and 82% for CTL CW3/701 .1 .
Lysis in the absence of antigenic peptides was 3% and 7%, respectively . 50% inhibition of lysis for reference peptide P198- .14-24 as competitor
was obtained at 8 x 10-sM for CTL CS.B28, and at 8.8 x 10-sM for CTL CW3/701.1 .
Antigen Peptide Sequence
Relative competitor activity for
antigenic peptide :
CS P.b. 252-260 CW3 170-182
HLA-A24 A24170-182 R Y L E N G K E T L Q R A
A24 170-179 RYLENGKETL 39 31
A24 170-178 RYLENGKET 2 2
A24 171-179 YLENGKETL 2 2
Influenza NP NP 147-158 TYQRTRALVRTG (1)" (V
NP 147-155 TYQRTRALV 45 43
NP 147-154 T Y Q R T R A L 0.4 0.4
NP 148-155 Y Q R T R A L V 5 .6 2.8
P198 P198 - .14-24 K Y Q A V T T T L E E (1)5 (1 ) s
P198 - .14-23 K Y Q A V T T T L E 0.65 0.8
P198 - .14-22 KYQAVTTTL 4.6 10
P198 - .14-21 KYQAVTTT 0.14 0.31608
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PEPTIDE CONCENTRATION logo M
.
￿
RecognitionofHLA-A24, influenza NP, and P198-truncated
s1Cr-labeled P815 target cells were incubated with the indicated
centrations ofA24 peptides (A) 170-182 (-A-), 170-179 (AP-),
f), or 171-179 (-C-); NP peptides (B) 147-158 (--"--), 147-
--), 147-154 (--"--), or 148-155 (--0--); or P198 peptides (C)
"..), 14-23 (.. "..), and 14-22 (. .0 . .), and 14-21 (.. "..), and
CTL clones A24/10.1 (A), NP.B25 (B), or P198.6 (C) at a 3:1
o. The assay was terminated after 4 h incubation at 37°C.
significant increase in competitor activity were found for each
antigenic system. The HLA-A24 peptide A24 170-179 was 80
>30-fold more active than the previously described peptide
A24 170-182. Similarly, the influenza peptide NP 147-155
was >40-fold more active than the longer peptide NP 147- 60
158, and peptide P198 - .14-22 was 5-10-fold more active
than the original 11-mer. Moreover, the most active trun-
cated peptides in terms of competitor activity were likewise 40
the most potent as antigens for CTL clones of the appro-
priate specificity (Fig. 3).
A Peptide Analogue that Incorporates the Tyr.. .Leu Motifand 20
a Pro6 Spacer Is a Potent Competitor for Kd-restricted Peptides.
In a previous study, we demonstrated that the peptide ana-
logue AYP5TLA that contains the HLAA24 residues Tyr171,
0
Thr178, and Leu179, which were identified as possible con-
tact residues for the Kd molecule, could function as an effi-
cient competitor for Kd-restricted antigenic peptides (16) . A 80
comparison of the truncated peptides found to be optimal T
as antigens and competitors in this study suggested that im- N
portant common features might be the presence of Tyr in c) 60
the second position and the residues Leu, Ile, or Val at the
COOH terminus (Table 3). We therefore analyzed a new, U
w
simplified series ofpolyproline analogues containing Tyr and a
to 40
Leu residues separated by a variable number of Pro residues.
The peptides were synthesized as pairs, with either Tyr or
z W
AlaTyr residues at the NH2 terminus.
U
cc 20
Of this series, the most efficient competitor for Kd-
LL a
restricted antigenic peptides was peptide AYP6L (Table 4).
The activity of the AYP6L analogue compares favorably
0
with that of two different Kd-restricted peptides, A24 170-
179 and P198 - .14-22, that contain the "Tyr. ..Leu" motif,
and with the previously described analogue AYP5TLA s
(Table 4). The nearly identical analogues with P7 or P5
spacers, AYP7L and AYP5L, were less active than the AYP6L
analogue by five fold and 170-fold, respectively. Analogues 6
with P4 spacers, YP4L and AYP4L, were completely inactive
in this system (data not shown). For each pair of peptides
containing a P5, P6, or P7 spacer, the peptide with the Ala- 40
Tyr NH2 terminus was at least 20-fold more active than its
counterpart with only Tyr. A very different pattern of ac-
tivity was observed when the same series of analogues was 20
tested in a competition assay with an Ld-restricted CTL
clone. In this case, none of the analogues was found to be
an efficient competitor (Table 4). The analogue for which
at least a low level competitor activity could be measured
in the Ld-restricted system, peptide YP7L, was N30-fold less
potent than the Ld-restricted reference peptide, pp89 168-
176. Moreover, in contrast to the Kd system, the analogue
Figure
AYP7L with an additional NH2-terminal Ala residue was peptides.
less potent than its counterpart without Ala. (final) co
170-178
155 (--
Discussion 14-24 (.
Individual MHC molecules can bind a large number of cells
E/T
from
rat
different peptides, and yet peptide/MHC interactions appear
to be largely MHC allele specific. Demonstrations that pep-
tides recognized in the context of the same MHC molecule
can compete specifically and reciprocally suggests that MHCTable 4.
￿
Polyproline-containing Analogues that Incorporate the K4-binding Motif "TYR...LEU" Are Potent Competitors
* Competitor activity for antigenic peptides PA CS 249-260 (10-'° M) and P91A-.12-24 (5 x 10-8 M) was assayed with CTL clones CS.B28
(Kd-restricted) and P91.6 (Ld-restricted), respectively. 50% inhibition of lysis for reference peptide AYP5TLA (in the experiment with CTL-CS-
B28) as a competitor was obtained at 2.6 x 10- 8 M, and that for reference peptide pp89 168-176 (in the experiment with CTL-P91.6) was ob-
tained at 3.5 x 10-7 M. The percent specific lysis in the absence of competitor was 61% for CTL-CS.B28 and 76% for CTL-P91.6. Lysis in the
absence of antigenic peptides was <4%.
molecules probably containa single peptide binding site (15,
30-34). In that case, peptides that interact with the same
MHC molecules might be expected to share structural fea-
turesthat allowbinding to the same ligand (11-13). Ourstudy
identifies a simple motif for Kd-restricted epitopes and also
suggests that optimal Kd-binding peptides are relatively
short.
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Our experiments document the marked increase in potency
for four Kd-restricted, but otherwise unrelated, CTL epi-
topes upon reduction in their length to 9 or 10 amino acid
residues. The increasedpotencyoftheshortenedpeptides was
apparent for their activity as antigens, in CTL recognition
assays, and as competitors in functional competition experi-
ments. To assess peptide/MHC binding more directly, we
* Antigen from which the CTL epitope sequence has been defined. All listed antigenic peptides can be recognized by Kd-restricted CTL with the
possible exception of the peptide pp89 168-176, which has been described as an Ld-restricted epitope (35), but that is also a potent Kd competitor
(16a), and the two peptide analogues which were designed by us as Kd competitors.
$ The residues corresponding to the putative Kd binding motif are underlined.
Antigen or analogue Sequence
Relative activity
antigenic
P.b. CS (Kd)
as competitor for
peptides*
P91A (Ld)
A24 170-179 R Y L E N G K E T L 2.2 <0.007
P198-.14-22 K Y Q A V T T T L 11 .8 <0.007
MCMV pp89 168-176 Y P H F M P T N L 0.11 (1)
Y. . .TL analogue A Y P5 T L A (1) <0.007
Y. . .L analogues Y P5 L 0.001 <0.007
A Y Ps L 0.024 <0.007
Y P6 L 0.13 <0.007
A Y P6 L 4.0 <0.007
Y P7 L 0.011 0.029
A Y P7 L 0.84 <0.007
Table 5. H-2V-restricted
Antigen*
Antigenic Peptides
Peptide
and Analogues Share a Simple Motif
Sequence$ Reference
HLA-CW3 CW3 170-182 RYLKNGKETLQRA 14
HLA-A24 A24 170-182 RYLENGKETTQRA 14
Influenza NP NP 147-158 TYQRTRALVRTG 19
P. berghei CS CS 249-260 NDDSYIPSAEKI 20
P. yoelii CS CS 277-288 NEDSYVPSAEQI 21
P198 P198-.14-24 KYQAVTTTLEE 18
Influenza HA HA 202-212 RTLYQNVGTYV 37
(A/NT/60/68)
HA 211-221 _YVSVGTST_LNK 37
Influenza HA HA 523-545 VYQILAIYATVAGSLSLIAMMAG 38
(A/JAP/57)
MCMV pp89 pp89 167-176 M_YPHFMPTN_L 35
Analogue AYPSTLA A_YPPPPPTL_A 16
Analogue AYP6L AYPPPPPPL This studyhave recently developed an assay based on photoaffinity labeling
(27) . In this assay, a photoreactive derivative of the H-2 Kd-
restricted peptide P . berghei CS 253-260 specifically labels Kd
molecules on living cells . We now show that the 9-mer P .
berghei and P . yoehi peptides (SYIPSAEKI and SYVPSAEQI)
inhibit the photoaffinity labeling more efficiently than the
corresponding 12-mers. These results strongly suggest that
the increased competitor activity of the shorter peptides is
indeed due to their higher affinity for the H-2 Kd molecule.
Moreover, the parallel increases in antigenic and competitor
activities upon truncation indicates that the different length
peptides present similar epitopes to the TCR .
Our observation that the nonamer NP sequenceTYQR
TRAW is the optimal antigenic peptide is in agreement with
a recent report (6) on the characterization of the naturally
processed NP peptide. Interestingly, the naturally processed
antigens corresponding to a Kb-restricted epitope from vesic-
ular stomatitis virus or to a Db-restricted epitope from the
influenza NP, were also found to be short peptides of eight
or nine amino acid residues, respectively (5, 6) . Moreover,
truncation analysis of peptides corresponding to an Ld-
restricted epitope from the mouse cytomegalovirus identified
a 9-mer as the optimal antigenic peptide (35) . It is tempting
to speculate that the optimal length for class I-restricted epi-
topes, either in synthetic or natural form, will generally be
8-10 residues.
Comparison of the short (9-mer and 10-mer) peptides that
were found to be optimal antigens in the present study sug-
gests that they share a simple structural motif that allows
binding to the Kd molecule. The motif is characterized by
a Tyr residue in the second position from the NH? terminus,
and a hydrophobic residue (Leu, Ile, or Val) at the COON
terminus (position 9 or 10) . The latter three amino acids possess
large aliphatic nonpolar side chains, and were found to be
grouped together in an analysis of the frequencies of amino
acid changes among homologous proteins of different spe-
cies (36) . Likewise, Tyr and Phe are included in another ex-
change group. In this context, we now have evidence that
for all four Kd-restricted epitopes analyzed in this study, the
Tyr residue can be replaced with Phe without a major loss
of antigenic or competitor activity (our unpublished obser-
vations) . One might then predict the occurrence of other
Kd-restricted epitopes in which the Tyr residue of the motif
would be replaced by Phe .
The actual involvement of the motif in Kd-binding ac-
tivity is clearly supported by several lines of experimental
evidence . Our earlier results analyzing four unrelated Kd-
restricted antigenic peptides demonstrated that the Tyr res-
idue was indeed critical for optimal interaction with Kd in
that substitution of Tyr with Ala residues resulted in at least
a 50-fold reduction in competitor activity (16, 16a) . The in-
clusion of a COON-terminal hydrophobic residue in the Kd-
binding motif was suggested in part by truncation experi-
ments, but its functional importance was demonstrated more
directly by amino acid substitution . For instance, the activity
of the 8-mer peptide P .h CS 253-260 (YIPSAEKI) and of
the 11-mer peptide P198- .14-24 (KYQAVTTTLEE) was de-
creased by at least 100-fold and 10-fold, respectively, upon
Ala substitution of the CS residue Ile26o (Romero et al .,
manuscript in preparation) and the P198 residue Leu22 (16a) .
Similarly, analysis of HLAA24 170-182 synthetic peptides
containing single amino acid substitutions indicated that
Leu179, which is the COOH-terminal residue of the optimal
10-mer peptide, was important for competitor activity (16) .
In that analysis substitution of Thr17s also reduced compet-
itor activity, indicating that in this case Thr178 may also
form part of the Kd-binding motif.
Evidence for the importance of the Kd motif comes so far
from experiments showing the loss of activity of peptides
upon deletion or substitution . We have also developed a more
positive approach to demonstrate the function of the motif.
This involves the incorporation of the motif in a completely
different molecular context . The peptide analogue AYP6L,
which contains the simple Kd motif "Tyr. . .Leu", was found
in this study to be a highly active competitor. Its activity
was over fivefold higher than the competitor activity of a
similar analogue, AYP5TLA, which contains the presumed
Kd-binding residues (Y. . . L) of the HLA-A24 peptide (16) .
The activity of both analogues appears to be allele specific
and, interestingly, deletion of the NH2-terminal Ala within
the analogues resulted in at least a 20-fold reduction in Kd
competitor activity (16 and Table 4) .
An analysis of the sequences of each of the Kd-restricted
CTL epitopes reported to date reveals that the motif is con-
tained within all of them (Table 5) . Moreover, in a recent
study (16a), we found that the Ld-restricted antigenic pep-
tide pp89 167-176 from a mouse cytomegalovirus (MCMV)
protein (35), competes not only with Ld-restricted peptides
but also with Kd-restricted peptides. This MCMV peptide
(MYPHFMPTNL) also contains the proposed Kd binding
motif. The occurrence of a common motif suggests that
Kd-restricted peptides might bind in a similar manner to the
MHC molecule . A model for the three-dimensional struc-
ture of the Kd molecule (16a) was recently developed based
on the atomic coordinates of the HLA-A2 crystal structure
(7) . Two pronounced cavities were apparent in the region
of the Kd model corresponding to the putative antigen-
binding site. These two Kd "pockets" could well accommo-
date the two Kd motif residues (Tyr and hydrophobic
residues like Leu, Ile, or Val) and thus provide a structural
correlate for the motif.
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